Wednesday, April 22, 2026 6:09:40 PM
SDL you have been an ultra bull on this stock since you started post here last year, perhaps even more bullish than I was when I went through my manic bull phase last October/November. I saw a huge pile of catalysts, and expected several of them to hit. So far, not a single one has come through.
As you work to gather retail shareholders for a show of solidarity, could you please provide the board with your current sober assessment of company circumstances and prospects. Let's make a quick list of catalysts that tantalized and (so far) let us down:
- China did not come through
- The rest of the world outside Europe has remained sporadic and trickle-y
- There has been no evidence to date, whatsoever, of any pickup in sales due to the new fenofibrate guidance
- Recordati has made no visible progress on key objectives, in particular getting back in the door in France and Germany. It's been 10 months.
- The "exclusive advisor" diatribe has resulted in literally nothing of any strategic substance to date
- SCOTUS granted cert on a case that it had no business taking
- We continue to tout the new formulation as a Holy Grail while in the meantime the company says literally nothing about that
I don't want to give up on this thing after having (rashly) concluded they had turned the corner and were headed upwards on a steep path. But Mighty Casey keeps swinging and missing. If he never hits the ball and never gets on base, and the Mudville 9 keep losing, over and over and over again -- how long do we keep showing up for their painful, soul-crushing games?
As you work to gather retail shareholders for a show of solidarity, could you please provide the board with your current sober assessment of company circumstances and prospects. Let's make a quick list of catalysts that tantalized and (so far) let us down:
- China did not come through
- The rest of the world outside Europe has remained sporadic and trickle-y
- There has been no evidence to date, whatsoever, of any pickup in sales due to the new fenofibrate guidance
- Recordati has made no visible progress on key objectives, in particular getting back in the door in France and Germany. It's been 10 months.
- The "exclusive advisor" diatribe has resulted in literally nothing of any strategic substance to date
- SCOTUS granted cert on a case that it had no business taking
- We continue to tout the new formulation as a Holy Grail while in the meantime the company says literally nothing about that
I don't want to give up on this thing after having (rashly) concluded they had turned the corner and were headed upwards on a steep path. But Mighty Casey keeps swinging and missing. If he never hits the ball and never gets on base, and the Mudville 9 keep losing, over and over and over again -- how long do we keep showing up for their painful, soul-crushing games?
"The biggest obstacles to our progress exist within our own lives in the form of cowardice and the tendency to give up. Breaking through these barriers will unleash a surging wave of change." -- Daisaku Ikeda
Recent AMRN News
- Earnings Report Shows Narrowing Losses as Amarin (AMRN) Advances Partner-Led Growth Strategy • IH Market News • 04/29/2026 02:19:17 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/29/2026 11:06:34 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/29/2026 11:05:15 AM
- Amarin Reports 2026 First Quarter Financial Results • GlobeNewswire Inc. • 04/29/2026 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/22/2026 09:00:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:02 PM
- Amarin to Report First Quarter 2026 Financial Results and Host Conference Call on April 29, 2026 • GlobeNewswire Inc. • 04/15/2026 12:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/10/2026 09:01:34 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/10/2026 09:00:20 PM
- American College of Cardiology (ACC) Scientific Sessions 2026 Underscore the Need for Complementary Therapies Including Icosapent Ethyl (IPE) in Treatment of Elevated Triglycerides and Cardiovascular Risk Reduction • GlobeNewswire Inc. • 04/08/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 08:30:11 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 03/30/2026 09:57:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/27/2026 09:00:07 PM
- Amarin Highlights Guideline Recommended Role of Icosapent Ethyl in Managing Cardiovascular Risk Following Release of Updated 2026 ACC/AHA/Multisociety Dyslipidemia Guideline • GlobeNewswire Inc. • 03/18/2026 12:30:00 PM
- New REDUCE-IT Data in Patients at Extreme Cardiovascular Risk and In Vitro Research on the Mechanistic Effects of Eicosapentaenoic Acid (EPA) on Lipoprotein(a) [Lp(a)] Oxidation to be Presented at the American College of Cardiology’s (ACC) Annual Scienti • GlobeNewswire Inc. • 03/16/2026 12:15:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/02/2026 10:31:01 PM
- Effects of Icosapent Ethyl on Risk and Duration of Hospitalizations and Death in REDUCE-IT® Post Hoc Analysis Published in the European Journal of Preventive Cardiology • GlobeNewswire Inc. • 03/02/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 12:05:26 PM
- Amarin Reports Fourth Quarter and Full Year 2025 Financial Results • GlobeNewswire Inc. • 02/25/2026 12:00:00 PM
- This American Heart Month Amarin Spotlights the Need to Prioritize Proven Widely Available Yet Underutilized Therapies in the Battle Against Cardiovascular Disease • GlobeNewswire Inc. • 02/23/2026 01:00:00 PM
